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AbstrACt
Introduction Depressive disorders are the most common, 
burdensome and costly mental disorders. Their treatments 
have developed through the past decades and we now 
have more than a dozen new generation antidepressants, 
while a series of guidelines have been published to provide 
recommendations over the years. However, there still 
may exist important gaps in this evidence synthesis and 
implementation process. Systematic reviews may not 
have been conducted in the most unbiased, informative 
and timely manners; guidelines may not have reflected 
the most up-to-date evidence; clinicians may not have 
changed their clinical decision-makings in accordance 
with the relevant evidence. The aim of this study is 
to examine the gaps between the ideally synthesised 
evidence, guideline recommendations and real-world 
clinical practices in the prescription of new generation 
antidepressants for major depression through the past 
three decades.
Methods and analysis We will conduct cumulative 
network meta-analyses (cNMAs) based on the 
comprehensive systematic review which has identified 
published and unpublished head-to-head randomised 
controlled trials comparing the following antidepressants 
in the acute phase treatment of major depression: 
agomelatine, amitriptyline, bupropion, citalopram, 
clomipramine, desvenlafaxine, duloxetine, escitalopram, 
fluoxetine, fluvoxamine, levomilnacipran, milnacipran, 
mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, 
trazodone, venlafaxine, vilazodone and vortioxetine. The 
primary outcomes will be the proportions of patients 
who responded (efficacy) and who withdrew from 
treatment for any reasons (acceptability). We will conduct 
a random effects cNMA to synthesise evidence and 
obtain a comprehensive ranking of all new generation 
antidepressants based on their surface under the 
cumulative ranking curves. We will identify series of 
international clinical practice guidelines for the treatment 
of major depression of adults and summarise their 
recommendations. We will estimate real-world prescription 
patterns of antidepressants in the nationally representative 
samples in USA in the Medical Expenditure Panel Survey. 
We will compare and evaluate the gaps between the 
rankings according to cNMAs conducted at 5-year 
intervals between 1990 and 2015, recommendations in 
guidelines published in the ensuing 5 years and actual 
practices thereafter.
Ethics and dissemination This review does not require 
ethical approval. We will disseminate our findings through 
publications in peer-reviewed journals and presentations 
at conferences.
trial registration number UMIN000031898.
IntroduCtIon 
Evidence-based medicine (EBM) is widely 
regarded as the guiding principle of today’s 
medical practices, for it can help integrate 
patients’ values, physicians’ experiences and 
scientific evidence derived from large-scale 
research to inform clinical decision-making.1 
strengths and limitations of this study
 ► This is one of the first studies to directly compare 
evidence derived from network meta-analyses, rec-
ommendations from guidelines and real-world clin-
ical practices.
 ► This study will show where the gaps may lie and 
how big they are, which can inform future efforts 
to bridge the gaps from scientific evidence to re-
al-world clinical practices.
 ► The cumulative network meta-analysis used in this 
study may evolve into prospectively designed se-
quential network meta-analysis which can be used 
as living accumulation of evidence and contribute to 
living guidelines.
 ► A major limitation of our study is that the real-world 
practices in nationally representative samples are 
available for USA only.
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To promote EBM, systematic reviews (SRs) including 
meta-analyses (MAs) should be conducted to produce a 
comprehensive summary of all relevant studies, clinical 
practice guidelines (CPGs) will be proposed based on 
such evidence synthesis, and physicians must update their 
shared decision-making processes in accordance with 
such guidelines.2 
Depressive disorders are the most common mental disor-
ders, making them the second leading cause of disability 
accounting for 8.2% of all years lived with disability in 
2010.3–5 Reflecting the high prevalence of major depres-
sive disorder (MDD) among people of working ages 
and the resulting dysfunctions, their economic burden 
was estimated at US$210.5 billion in US alone in 2010.6 
Antidepressants are widely used in the treatment of 
MDD, and a host of new generation antidepressants have 
been approved into the market in the past two to three 
decades. Given the enormity of burdens due to MDD on 
patients and society, various institutions worldwide have 
produced CPGs for physicians. It was as early as in 1993 
that American Psychiatric Association (APA),7 British 
Association for Psychopharmacology (BAP)8 and Agency 
for Health Care Policy and Research (AHCPR)9 proposed 
the first version of their guidelines, followed by other 
associations like National Institute for Health and Care 
Excellence (NICE) from UK10 and Canadian Network for 
Mood and Anxiety Treatments from Canada.11 Most of 
these guidelines have been updated every several years 
since.
However, there are still several important barriers that 
may impede physicians and patients from making optimal 
clinical decisions. First, it has become increasingly known 
that a substantive amount of trials of antidepressants 
remain unpublished and were not included in contem-
porary SRs, a fact which most likely introduces publica-
tion bias into the results of SRs and thus undermines the 
credibility of guidelines.12 Second, it has been reported 
that there is approximately 8 months to more than 1-year 
lag between the last search date in the literature and the 
publication of an SR,13 14 and in total 2.5–6.5 years interval 
between the publication dates of the latest primary 
studies and the publication date of SRs.15 It was estimated 
that 7% of the published SRs were already out of date at 
the time of publication.16 Third, few of the available CPGs 
provide specific and precise recommendations in the 
choice of antidepressants, as pooled evidence has been 
given conflicting interpretations.17 18 Fourth, physicians’ 
behaviours are notoriously difficult to influence.19–21 The 
road from randomised evidence to actual practices thus 
appears formidable.22
The aim of the present study is to examine how the accu-
mulating body of evidence should have been assembled 
and reflected in guidelines, and then transferred into real 
practices in the prescription of new generation antide-
pressants for MDD through the past three decades. The 
evidence we will consider comes from a uniquely compre-
hensive dataset prepared by Group of Researchers Inves-
tigating Specific Efficacy of individual Drugs for Acute 
depression  (GRISELDA).23 24 It comprises data from 522 
published and unpublished double-blind randomised 
controlled trials (RCTs) of new generation and other anti-
depressants in the acute treatment of depression. Capital-
ising on this, we will use cumulative network MA (cNMA) 
to summarise the development of accumulated evidence 
over time.25–27 When two or more treatment alternatives 
are available, as in the case of MDD, NMA can summarise 
the relative effects of all treatments options by combining 
both direct and indirect comparisons28; because they 
use all direct and indirect evidence, they can produce 
strong evidence concerning relative efficacy more often 
and earlier than conventional, pairwise MAs.29 We will 
examine the specific recommendations in the interna-
tionally representative CPGs. The real-world prescrip-
tion practices will be collated from Medical Expenditure 
Panel Survey (MEPS) in USA, which is a large-scale yearly 
healthcare survey of representative samples of families 
and individuals in the USA.30 We predict that there are 
important gaps in the evidence synthesis and implemen-
tation process. Our study will evaluate and narratively 
summarise how big these gaps are and where mainly they 
exist, and will provide valuable information necessary 
to direct future paths to bridge the gaps from scientific 
evidence to real-world clinical practice.
MEthods
srs of rCts of new generation antidepressants and cnMA
Study eligibility
The cNMAs in this study will be based on the SR which has 
identified all published and unpublished double-blinded 
head-to-head RCTs comparing any of the following new 
generation antidepressants in the acute phase treat-
ment of adults with MDD up to January 201623 24: we will 
consider all new generation antidepressants approved by 
drug agencies of USA, Europe or Japan including agomel-
atine, bupropion, citalopram, desvenlafaxine, duloxetine, 
escitalopram, fluoxetine, fluvoxamine, levomilnacipran, 
milnacipran, mirtazapine, paroxetine, reboxetine, 
sertraline, venlafaxine, vilazodone and vortioxetine.
The GRISELDA dataset also contains two older tricyclic 
antidepressants (TCAs) recommended by WHO Model 
List of Essential Medicines (amitriptyline and clomip-
ramine) and two drugs with distinct effect and side effect 
profiles (trazodone and nefazodone): they will constitute 
evidence set31 in the NMAs which serves to connect and 
strengthen the network.
We will include in the MA only study arms which 
administered the drugs within dose ranges approved by 
the regulatory agencies. Because the inclusion of place-
bo-controlled trials may violate the transitivity assumption 
of NMA in depression studies,32–36 and because we will be 
comparing the evidence from cNMA with real-world prac-
tice, we will only include RCTs comparing active drugs 
and exclude placebo-controlled studies in the current 
cNMAs.
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Study identification and data extraction
GRISELDA has searched the following databases without 
language restrictions for published articles: Cochrane 
Central Register of Controlled Trials, CINAHL, EMBASE, 
LiLACS, MEDLINE, MEDLINE In-Process and PsycINFO 
up to January 2016. We performed manual searches of 
references of included articles. We also searched for 
published, unpublished and ongoing RCTs in drug-ap-
proval agencies’ documents, company websites, inter-
national trial registries and through contact with 
pharmaceutical companies and other relevant organ-
isations. Where necessary, we contacted study authors 
directly to get online supplementary materials for further 
information. The risk of bias of each included study was 
assessed according to the guide proposed in the Cochrane 
Collaboration Handbook.37
Study identification, data extraction and risk of bias 
assessment of the included studies were all performed 
independently by two researchers, and any disagree-
ments were resolved through discussion or in consulta-
tion with a third reviewer. For further details of the SR 
process, please see the published protocol and the main 
GRISELDA paper.23 24
Statistical analyses
We will conduct cNMA every 5 years in consideration of 
the speed of accumulating new trials and publication of 
guidelines for MDD. According to previous studies which 
indicated that the latest search of database was about 
1 year before publication of SRs,13–15 cNMA at any time 
point will include all trials completed up to 1 year before 
that date. For trials whose completion year is not available, 
publication date will be used; when neither is known, the 
date of approval of the drug by regulatory agencies will 
be used as the study completion date. Thus, studies with 
a known completion year before the proposed cNMA will 
be included in the relevant cNMA even if the data were 
published after that year. Only such cNMA can present 
the best available, publication bias-free evidence, on 
which practice guidelines should ideally be founded.
For NMA, transitivity assumption is the principle. Since 
we have confirmed the transitivity assumption of the 
whole dataset in the final NMA,24 we will not validate it 
at every time point reanalysis. In our previous study, we 
investigated the distribution of the following potential 
effect modifiers across treatment comparison: (1) study 
year; (2) sponsorship; (3) depressive severity at baseline; 
(4) dosing schedule; (5) proportion of participants allo-
cated to placebo; (6) number of recruiting centres (single-
centre vs multicentric studies). We evaluated consistency 
and heterogeneity in the entire network using various 
tests and metrics and we have found little evidence of 
inconsistency and heterogeneity.24
Our primary outcomes are (1) efficacy of the interven-
tion in terms of response rate defined as the proportion 
of patients who showed a reduction of at least 50% on 
the total depression severity score compared with base-
line and (2) acceptability of the intervention in terms of 
all-cause discontinuation rate defined as the proportion 
of patients who leave the study early for any reason. We 
have extracted the outcome data at a time point as close 
to 8 weeks as possible: if outcomes at 8 weeks were not 
available, we recorded data between 4 and 12 weeks.
We will not adjust for multiple comparisons in succes-
sive NMAs as we are not testing particular hypotheses for 
specific comparisons among antidepressants.
We will use the surface under the cumulative ranking 
curve to estimate ranking probabilities for each interven-
tion with regard to the two primary outcomes. We will 
show ranked forest plots of ORs with 95% CI in compar-
ison with a common comparator as a sensitivity analysis: 
we will use fluoxetine as the common comparator as it is 
the most frequently used drug in the trials network.24
We will use STATA V.14 (StataCorp) to conduct 
cNMA.38 39
Identification and extraction of recommendations in 
guidelines
We will use a series of CPGs as our benchmark in compari-
sons. English written guidelines proposed by government 
agencies (such as NICE) or professional academic soci-
eties (such as APA) will be included. Due to the ambiguity 
and subjectivity associated with the Appraisal of Guide-
lines Research and Evaluation II (AGREE) instrument 
for quality assessment of guidelines,40 we will not apply 
AGREE instrument in the appraisal of guidelines, but we 
will describe the methodology of each guideline develop-
ment in online supplementary materials. As a result, we 
will extract recommendations for specific antidepressants 
or for specific classes of antidepressants from internation-
ally representative guidelines listed below:
1. Practice guidelines for the treatment of patients with 
MDD published by APA, in 1993, 2000, 2010, respec-
tively.7 41 42
2. Guidelines for management of depression proposed 
by NICE, in 2004, 2009 and 2018.10 43 44
3. Guidelines for treating depressive disorders with anti-
depressants proposed by BAP, in 1993, 2000, 2008 and 
2015.8 45–47
4. CPGs for treatment of major depression proposed by 
AHCPR in 1993.9
We will extract recommendations with respect to acute 
phase treatment for adult patients with a primary diagnosis 
of unipolar non-psychotic major depression. We define 
recommendations as statements used in CPGs involving 
the words like ‘recommend’, ‘must’, ‘necessary’, ‘should’, 
‘appropriate’ or other words indicating instructions from 
guidelines. Basic information of the guideline (institu-
tion, year, targeted patients, diagnostic criteria, etc), phar-
macotherapy recommendations as acute phase treatment 
(particular drugs and categories recommended and least 
recommended, severity of the disease, etc), pharmaco-
therapy recommendations for patients who have no satis-
factory response to initial treatment will be recorded in 
detail, in order to be compared with results from cNMA 
and real world. We will also collect the quality of evidence 
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and strength of recommendations backing extracted 
recommendations. Two researchers will independently 
identify recommendations and extract information from 
CPGs. Any disagreement will be resolved through discus-
sion or in consultation with a third researcher.
real-world prescriptions data extraction
We will extract real-world prescription data from the 
MEPS database.30 MEPS is a database composed of large-
scale surveys of families and individuals and their medical 
providers, collecting data on the use of specific health 
services, the cost and the health insurance in the USA. 
The survey started in 1996. MEPS has two major compo-
nents, the household component and the insurance 
component, both of which provide data on a yearly basis. 
In the household component, a representative sample of 
families and individuals are interviewed every year and 
detailed information including demographic characteris-
tics, health status, use of medical services, specific medi-
cations, cost for each person is collected. Each annual 
MEPS household sample size is about 15 000 households. 
This set of households is a subsample of households 
participating in the previous year’s National Health Inter-
view Survey (NHIS) led by the National Center for Health 
Statistics. The NHIS sampling frame gives a nationally 
representative sample of the non-institutionalised popula-
tion in the USA, and oversamples of blacks and Hispanics. 
In 2006, after implementing a new sample design, Asian 
population has been included in order to deal with the 
oversampling issues. To correct for oversampling and for 
non-response, each participant is given a weight adjusting 
for non-response over time and some poststratification 
variables (region, race/ethnicity, sex, age, poverty status 
and etc), in order to produce national estimates.30 MEPS 
database has been used for the analysis of health expen-
ditures and real-world prescriptions of specific drugs in 
several studies.48–50
Participants
We will include those who have been classified as ‘depres-
sive disorders’ in the category of ‘657 mood disorder’, of 
either sex and aged 18 years or older. The corresponding 
International Statistical Classification of Diseases and 
Related Health Problems 10th Revision (ICD-10) 
numbers are: 29620, 29621, 29622, 29623, 29624, 29625, 
29626, 29630, 29631, 29632, 29633, 29634, 29635, 29636, 
311. MEPS database only code the diagnosis for the first 
three digits using ICD numbers (296, 311).
Interventions
Of the 21 antidepressants included in the GRISELDA 
network, the following drugs will not be included 
among the drugs prescribed for depressive disorders 
in MEPS: agomelatine and reboxetine have not been 
approved by US  Food and Drug Administration (FDA) 
for marketing in USA, fluvoxamine has an indication for 
obsessive–compulsive disorder but not for depression and 
milnacipran for fibromyalgia only. On the other hand, 
there are many antidepressants, other than new gener-
ation antidepressants, which may have been prescribed 
especially in older days, such as imipramine, desipramine, 
doxepin or nortriptyline. Although our focus of compar-
ison is new generation antidepressants, we will extract the 
frequency of prescription of all antidepressants in the 
MEPS study. Using the National Drug Code Directory,51 
which included all registered drugs in FDA, we identified 
all antidepressants ever used in the USA as the following: 
(1) TCAs (Established Pharmacologic Class [EPC]): 
amitriptyline, amoxapine, clomipramine, desipramine, 
doxepin, imipramine, nortriptyline, protriptyline, trimip-
ramine; (2) Serotonin reuptake inhibitor (EPC): citalo-
pram, escitalopram, fluoxetine, nefazodone, paroxetine, 
sertraline, trazodone; (3) Serotonin and norepinephrine 
reuptake inhibitor (EPC): desvenlafaxine, duloxetine, 
venlafaxine, levomilnacipran; (4) No pharm class: bupro-
pion, mirtazapine, vilazodone, vortioxetine. All the 24 
listed antidepressants will be searched in MEPS during 
data extraction.
Data extraction
We will extract prescription data for antidepressants 
listed above in the year 1996, 2000, 2005, 2010 and 2015 
(table 1). Since diagnostic labels available MEPS data 
cannot distinguish unipolar depression from bipolar 
depression and psychotic depression, both of which 
require different drug treatments than unipolar depres-
sion, we will exclude those patients who are concom-
itantly taking mood stabilisers or any antipsychotics. 
According to the National Drug Code Directory,51 
mood stabiliser (EPC) include: carbamazepine, dival-
proex, lamotrigine, lithium, valproate, valproic acid; 
and phenothiazine (EPC), typical antipsychotics (EPC) 
and atypical antipsychotics (EPC) include: aripiprazole, 
asenapine, brexpiprazole, cariprazine, chlorpromazine, 
clozapine, fluphenazine, haloperido, iloperidone, loxa-
pine, lurasidone, molindone, olanzapine, paliperidone, 
Table 1 Time periods for comparisons in our study
Trials 
(completion 
year*)
Cumulative 
NMAs
CPGs 
(publication 
year)
Real-world 
prescriptions 
(MEPS data 
file year)
Present Present 2016 to present –
2009 2010 2010 to 2015 2015
2004 2005 2005 to 2009 2010
1999 2000 2000 to 2004 2005
1994 1995 1995 to 1999 2000
1989 1990 1990 to 1994 1996†
*For trials whose completion year is not available, publication date 
will be used; when neither is known, the date of approval of the 
drug by regulatory agencies will be used as its completion date.
†As MEPS database started with 1996, so we will use data from 
1996 for the analysis of prescriptions.
CPGs, clinical practice guidelines; MEPS, Medical Expenditure 
Panel Survey; NMAs, network meta-analyses.
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perphenazine, pimavanserin, quetiapine, risperidone, 
thioridazine, thiothixene, ziprasidone. We will exclude 
all participants taking any of these drugs concomitantly 
with an antidepressant.
Every participant in one MEPS cohort (called ‘panel’ 
in MEPS) is interviewed five times (called ‘rounds’) for 
2 years. For example, the file of 2015 contains the 2015 
portion of round 3 and rounds 4 and 5 for panel 19, as 
well as rounds 1, 2 and the 2015 portion of round three for 
panel 20 (see figure 1).30 We will check the prescription 
of antidepressants at round 2 from panel 20 and round 
4 from panel 19 (similar patterns in other given years), 
because each participant, either from panel 19 or 20, must 
have this intermediate round of interview within 2015, 
and we will use it as a cross-sectional investigation. We 
will use the total number of patients with the diagnosis of 
depression and who are on antidepressant monotherapy 
but not taking mood stabilisers and antipsychotics (listed 
above) concomitantly at this round as denominator, and 
the prescription for a particular drug as monotherapy as 
numerator. Given lack of precise information for medi-
cation schedule (eg, start time of diagnosis, primary 
medication, time of start and change of medication), 
we will not be able to restrict the prescriptions to incep-
tion prescriptions in the acute phase treatment of MDD, 
and the results will include both incident and prevalent 
uses. As MEPS dataset gives each participant a sample 
weight according to non-response and poststratification 
variables, we will use the sample weights to estimate the 
nationally representative number of patients on a specific 
therapy. Finally, the ranking of the of prescriptions will 
then be based on the estimated numbers of prescriptions 
in the general US population.
We will use Python V.3.6 to extract data from MEPS 
dataset.
Comparison between cnMA, CPGs and real-world 
prescriptions
We propose that a cNMA at a specific time point (eg, 2000) 
should be taken as a reference for any guidelines that are 
going to be published in the next 5 years (eg, 2000–2004), 
and then inform real-world prescriptions afterwards (eg, 
2005 and after). We will therefore compare the results 
of NMA, CPG recommendations and real-world practice 
in these corresponding years, and the trend between 
these time points will also be taken into considerations. 
Table 1 shows the time periods for comparisons. We will 
assess if the recommendable sets estimated from cNMA 
(ie, drugs which have good balance between efficacy and 
acceptability) are reflected in the drugs recommended 
by guidelines, which then will be compared with the 
rankings in actual clinical practice. Moreover, as MEPS 
is a database from the USA, we will attempt to compare 
results from MEPS with the US guidelines APA. We will 
describe the possible differences and explore the time lag 
from the ideally available evidence to guideline recom-
mendations and from guideline recommendations to the 
real-world practices. We will also investigate the poten-
tial factors which may influence the actual prescriptions 
including side effects profiles of specific drugs, year of 
FDA approval, the price of the drug while on patent, and 
the year of patent expiration of each drug.
Patient and public involvement
This research protocol was written without patient 
involvement. Patients were not invited to comment on 
the study design and were not consulted to develop 
patient-relevant outcomes or interpret the results. 
Patients were not expected to contribute to conducting 
this study and to the writing of this document for read-
ability or accuracy.
dIsCussIon
We have presented the study protocol for investigating 
the gaps between ideally synthesised evidence, guideline 
recommendations and real-world clinical practices in 
the prescriptions of new generation antidepressants for 
unipolar MDDs.
Our study has several strengths. It is one of the first 
studies to make comparisons between pooled evidence 
derived from cNMAs, recommendations from guidelines 
and real-world clinical practices. In the cNMA, we will 
use the comprehensive dataset from our previous study,24 
Figure 1 Survey structure of 2015 file in Medical Expenditure Panel Survey (MEPS).30
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which included both published and unpublished trials. 
And we will use MEPS database, which collect detailed 
information of health status and specific medications 
from a representative sample in the USA, as a reflection 
of real-world prescription profile. We expect this study 
to show the gaps between evidence and practice, and 
our findings will inform future developments of EBM. 
For instance, the cNMA used in this study may eventu-
ally evolve into prospectively designed sequential NMA 
which can be used to continuously update evidence and 
contribute to living guidelines, which is a guideline that 
is updated as soon as new evidence becomes available, so 
that it can provide timely and trustworthy suggestions for 
decision-makers.15 52 53
There are some limitations to our study. First, MEPS 
does not allow us to extract very precise information, 
including whether the antidepressant is being used as 
first-line or later treatments. This may lower the compara-
bility between the cNMA of acute phase treatment studies 
of unipolar depression and the real-world practices, as 
patients on continuation/maintenance treatment may 
continue using the same antidepressants after guideline 
recommendations for acute phase treatment change. 
However, it must be noted that three-quarters of patients 
who initiate antidepressant treatment discontinue the 
drug within 90 days54, suggesting that the majority of 
the patients in MEPS database represent initial prescrip-
tions. Second, MEPS is a US database so we will not be 
able to make comparisons between guideline recommen-
dations and actual practices in other countries. Lastly, 
the reasons behind the differences between evidence 
and practice may be very complicated and we will need 
to factor in various potential confounding factors such 
as the side effects, marketing efforts of pharmaceutical 
companies and local regulations such as price or patent 
status of a particular drug.15 55 56
In conclusion, our study represents a unique inquiry 
into gaps from evidence to real-world practices, and may 
provide valuable insights into future developments of 
EBM.
Author affiliations
1Department of Health Promotion and Human Behavior, School of Public Health in 
the Graduate School of Medicine, Kyoto University, Kyoto, Japan
2School of Medicine, Paris Descartes University, Paris, France
3Epidemiology and Statistics, Sorbonne Paris Cité Research Center, METHODS 
Team, Paris, France
4Cochrane France, Paris, France
5Hospital Care Research Unit, Hyogo Prefectural Amagasaki General Medical Center, 
Amagasaki, Japan
6Department of Health Sciences, Università degli Studi di Milano, Milan, UK
7Department of Psychiatry, University of Oxford, Oxford, UK
8Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Acknowledgements We would like to thank all the constructive comments and 
advices from the members from the meta-epidemiological study group in the 
School of Public Health, Kyoto University.
Contributors YL and TAF conceived the study and drafted the protocol. ACh, YK, 
EGO, YO, ACi and GS assisted in the study design and critically revised the protocol. 
All authors gave final approval of the version to be published.
Funding This study was supported in part by JSPS Grant-in-Aid for Scientific 
Research (Grant Number17k19808) to TAF. 
disclaimer The funder has no role in study design, data collection, data analysis, 
data interpretation, writing of the report or in the decision to submit for publication.
Competing interests TAF has received lecture fees from Janssen, Meiji, 
Mitsubishi-Tanabe, MSD and Pfizer. He has received research support from 
Mitsubishi-Tanabe and Mochida. ACi is supported by the NIHR Oxford Cognitive 
Health Clinical Research Facility, and was expert witness for Accord Healthcare for 
a patent issue about quetiapine extended release.
Patient consent Not required.
Ethics approval This study does not require institutional review board approval.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a 
quarter century on. Lancet 2017;390:415–23.
 2. Haynes RB. Of studies, syntheses, synopses, summaries, and 
systems: the "5S" evolution of information services for evidence-
based healthcare decisions. Evid Based Med 2006;11:162–4.
 3. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and 
national disability-adjusted life years (DALYs) for 306 diseases 
and injuries and healthy life expectancy (HALE) for 188 countries, 
1990-2013: quantifying the epidemiological transition. Lancet 
2015;386:2145–91.
 4. GBD 2015 DALYs and HALE Collaborators. Global, regional, and 
national disability-adjusted life-years (DALYs) for 315 diseases and 
injuries and healthy life expectancy (HALE), 1990-2015: a systematic 
analysis for the Global Burden of Disease Study 2015. Lancet 
2016;388:1603–58.
 5. WHO. Depression: fact sheet. Geneva: World Health Organisation, 
2017.
 6. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive 
disorders by country, sex, age, and year: findings from the global 
burden of disease study 2010. PLoS Med 2013;10:e1001547.
 7. American Psychiatric Association. Practice guideline for major 
depressive disorder in adults. Am J Psychiatry 1993;150:1–26.
 8. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for 
treating depressive illness with antidepressants: a statement from 
the british association for psychopharmacology. J Psychopharmacol 
1993;7(1 Suppl):19–23.
 9. AHCPR Clinical Practice Guidelines N. Depression in Primary Care 
(Volume 2: Treatment of Major Depression, 1993. https://www. ncbi. 
nlm. nih. gov/ books/ NBK52234/#! po= 16. 6667.
 10. Health NCCfM. Management of depression in primary and secondary 
care, 2004. https://www. nice. org. uk/ guidance/ CG23.
 11. Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for 
Mood and Anxiety Treatments (CANMAT) clinical guidelines for the 
management of major depressive disorder in adults. Introduction. J 
Affect Disord 2009;117:S1–S2.
 12. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of 
antidepressant trials and its influence on apparent efficacy. N Engl J 
Med 2008;358:252–60.
 13. Beller EM, Chen JK, Wang UL, et al. Are systematic reviews up-to-
date at the time of publication? Syst Rev 2013;2:36.
 14. Sampson M, Shojania KG, Garritty C, et al. Systematic reviews can 
be produced and published faster. J Clin Epidemiol 2008;61:531–6.
 15. Elliott JH, Turner T, Clavisi O, et al. Living systematic reviews: an 
emerging opportunity to narrow the evidence-practice gap. PLoS 
Med 2014;11:e1001603.
 16. Shojania KG, Sampson M, Ansari MT, et al. How quickly do 
systematic reviews go out of date? A survival analysis. Ann Intern 
Med 2007;147:224–33.
 17. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and 
acceptability of 12 new-generation antidepressants: a multiple-
treatments meta-analysis. Lancet 2009;373:746–58.
 18. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits 
and harms of second-generation antidepressants for treating major 
 o
n
 13 Decem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023222 on 9 December 2018. Downloaded from 
7Luo Y, et al. BMJ Open 2018;8:e023222. doi:10.1136/bmjopen-2018-023222
Open access
depressive disorder: an updated meta-analysis. Ann Intern Med 
2011;155:772–85.
 19. Forsetlund L, Bjorndal A, Rashidian A, et al. Continuing education 
meetings and workshops: effects on professional practice and health 
care outcomes. Cochrane Database Syst Rev 2009;2:CD003030.
 20. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on 
professional practice and healthcare outcomes. Cochrane Database 
Syst Rev 2012;6:CD000259.
 21. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: 
effects on professional practice and health care outcomes. Cochrane 
Database Syst Rev 2007;4:CD000409.
 22. Balas EA, Boren SA. Managing clinical knowledge for health care 
improvement. Yearb Med Inform 2000;1:65–70.
 23. Furukawa TA, Salanti G, Atkinson LZ, et al. Comparative efficacy 
and acceptability of first-generation and second-generation 
antidepressants in the acute treatment of major depression: protocol 
for a network meta-analysis. BMJ Open 2016;6:e010919.
 24. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and 
acceptability of 21 antidepressant drugs for the acute treatment 
of adults with major depressive disorder: a systematic review and 
network meta-analysis. Lancet 2018;391:1357–66.
 25. Antman EM, Lau J, Kupelnick B, et al. A comparison of results of 
meta-analyses of randomized control trials and recommendations 
of clinical experts. Treatments for myocardial infarction. JAMA 
1992;268:240–8.
 26. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-
analysis of therapeutic trials for myocardial infarction. N Engl J Med 
1992;327:248–54.
 27. Rouse B, Cipriani A, Shi Q, et al. Network meta-analysis for clinical 
practice guidelines: a case study on first-line medical therapies for 
primary open-angle glaucoma. Ann Intern Med 2016;164:674–82.
 28. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and 
technical challenges in network meta-analysis. Ann Intern Med 
2013;159:130–7.
 29. Nikolakopoulou A, Mavridis D, Furukawa TA, et al. Living network 
meta-analysis compared with pairwise meta-analysis in comparative 
effectiveness research: empirical study. BMJ 2018;360:k585.
 30. Quality USAfHRa. Medical Expenditure Panel Survey (MEPS). https:// 
meps. ahrq. gov/ mepsweb/.
 31. Ades AE, Caldwell DM, Reken S, et al. Evidence Synthesis of 
Treatment Efficacy in Decision Making: A Reviewer's Checklist. 
London, 2012.
 32. Rutherford BR, Sneed JR, Roose SP. Does study design influence 
outcome?. The effects of placebo control and treatment duration in 
antidepressant trials. Psychother Psychosom 2009;78:172–81.
 33. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo 
arm influence response to active antidepressant treatment in 
randomized controlled trials? Results from pooled and meta-
analyses. J Clin Psychiatry 2010;71:270–9.
 34. Furukawa TA, Cipriani A, Atkinson LZ, et al. Placebo response 
rates in antidepressant trials: a systematic review of published and 
unpublished double-blind randomised controlled studies. Lancet 
Psychiatry 2016;3:1059–66.
 35. Furukawa TA, Cipriani A, Leucht S, et al. Is placebo response in 
antidepressant trials rising or not? A reanalysis of datasets to 
conclude this long-lasting controversy. Evid Based Ment Health. In 
Press. 2018;21:1–3.
 36. Salanti G, Chaimani A, Furukawa TA, et al. Impact of placebo arms 
on outcomes in antidepressant trials: systematic review and meta-
regression analysis. Int J Epidemiol. In Press. 2018;47:1454–64.
 37. Collaboration TC. Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0. 2011. http://www. cochrane- handbook. 
org.
 38. Salanti ACG. Visualizing assumptions and results in network meta-
analysis: The network graphs package. Stata Journal, StataCorp LP 
2015;15:905–50.
 39. White IR. Network meta-analysis. Stata Journal, StataCorp LP 
2015;15:951–85.
 40. Scott NA, Moga C, Harstall C. Making the AGREE tool more user-
friendly: the feasibility of a user guide based on Boolean operators. J 
Eval Clin Pract 2009;15:1061–73.
 41. American Psychiatric Association. Practice guideline for the 
treatment of patients with major depressive disorder (revision). Am J 
Psychiatry 2000;157:1–45.
 42. Association AP. Practice Guideline for the Treatment of Patients 
With Major Depressive Disorder. 3rd Edition, 2010. Available from. 
http://www. psychiatryonline. com/ pracGuide/ pracGuideTopic_ 7. 
aspx.
 43. NICE. Depression in adults: recognition and management, 2010. 
https://www. nice. org. uk/ guidance/ cg90.
 44. NICE. Depression in adults: treatment and management, 2018.
 45. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for 
treating depressive disorders with antidepressants: a revision of 
the 1993 British Association for Psychopharmacology guidelines. 
British Association for Psychopharmacology. J Psychopharmacol 
2000;14:3–20.
 46. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based 
guidelines for treating depressive disorders with antidepressants: 
a revision of the 2000 British Association for Psychopharmacology 
guidelines. J Psychopharmacol 2008;22:343–96.
 47. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines 
for treating depressive disorders with antidepressants: A revision of 
the 2008 British Association for Psychopharmacology guidelines. J 
Psychopharmacol 2015;29:459–525.
 48. Lichtenberg FR. Are the benefits of newer drugs worth their cost? 
Evidence from the 1996 MEPS. Health Aff 2001;20:241–51.
 49. Miller JD, Foster T, Boulanger L, et al. Direct costs of COPD in the 
U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. 
COPD 2005;2:311–8.
 50. Sullivan PW, Ghushchyan VH, Slejko JF, et al. The burden of adult 
asthma in the United States: evidence from the Medical Expenditure 
Panel Survey. J Allergy Clin Immunol 2011;127:363–9.
 51. FDA. National Drug Code Directory, 2018. https://www. fda. gov/ 
drugs/ informationondrugs/ ucm142438. htm.
 52. Akl EA, Meerpohl JJ, Elliott J, et al. Living systematic reviews: 
4. Living guideline recommendations. J Clin Epidemiol 
2017;91:47–53.
 53. Elliott JH, Synnot A, Turner T, et al. Living systematic review: 1. 
Introduction-the why, what, when, and how. J Clin Epidemiol 
2017;91:23–30.
 54. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant 
treatment for adults with depression in the United States. Am J 
Psychiatry 2006;163:101–8.
 55. Clemens J, Gottlieb JD. Do physicians' financial incentives 
affect medical treatment and patient health? Am Econ Rev 
2014;104:1320–49.
 56. Yeh JS, Franklin JM, Avorn J, et al. Association of industry payments 
to physicians with the prescribing of brand-name statins in 
massachusetts. JAMA Intern Med 2016;176:763–8.
 o
n
 13 Decem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023222 on 9 December 2018. Downloaded from 
